David Rind, ICER CMO
August 5, 2021 09:24 AM EDT
FDA+

ICER of­fers fi­nal ver­dict against Bio­gen's ad­u­canum­ab: No proof it works, clear prospect of harm, wild­ly over­priced

John Carroll

Editor & Founder

The folks at ICER have crunched the da­ta on ad­u­canum­ab. The in­de­pen­dent drug watch­dog brought to­geth­er a pan­el of Alzheimer’s ex­perts to re­view the tri­al …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times